Haleon (LON:HLN) Earns Sector perform Rating from Royal Bank Of Canada

Haleon (LON:HLN)‘s stock had its “sector perform” rating reaffirmed by investment analysts at Royal Bank Of Canada in a report issued on Thursday,Digital Look reports. They currently have a GBX 370 price objective on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 8.28% from the stock’s previous close.

HLN has been the topic of a number of other reports. Berenberg Bank reiterated a “buy” rating and set a GBX 512 price objective on shares of Haleon in a research note on Thursday. Deutsche Bank Aktiengesellschaft decreased their target price on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 450 target price on shares of Haleon in a research note on Monday, March 30th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of GBX 407.

Haleon Stock Performance

Shares of LON:HLN traded up GBX 1.70 during midday trading on Thursday, reaching GBX 341.70. 145,580,578 shares of the company traded hands, compared to its average volume of 33,200,895. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26. Haleon has a 12 month low of GBX 325.10 and a 12 month high of GBX 419.50. The firm has a market capitalization of £30.47 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 1.49 and a beta of 0.33. The firm’s fifty day moving average price is GBX 372.83 and its two-hundred day moving average price is GBX 370.84.

Haleon (LON:HLN) last released its quarterly earnings data on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.43% and a net margin of 12.59%. On average, equities analysts expect that Haleon will post 19.5033282 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Brian McNamara sold 63,012 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total transaction of £231,884.16. 0.01% of the stock is owned by corporate insiders.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.